Stryker Corporation (SYK)
Stryker: Medtech On Sale, Benefiting From Industry Growth
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Stryker: The Reshaped Product Portfolio Will Drive Growth
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker Vs. Intuitive Surgical: Stryker's Joint-Replacement Moat Over Intuitive's Premium Valuation
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Stryker (SYK) Moves 5.3% Higher: Will This Strength Last?
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
Stryker faces cyberattack fallout, but strong procedure demand, record Mako adoption and global expansion continue to support long-term growth.
Stryker Launches TPX HD Power Tool for Complex Orthopedic Procedures
SYK launches TPX HD, a small bone power tool built for complex revisions, MIS and oral maxillofacial cases with higher torque and speed.
Stryker Launches Pangea Plating System in Europe for Fracture Fixation
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
Stryker Corporation (SYK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stryker Corporation (SYK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stryker Q1 Earnings & Sales Miss Estimates on Cyber Disruption
SYK misses Q1 earnings and revenue estimates as a cyber incident disrupts production, dents margins, and slows growth despite gains across key segments.
Stryker Corporation (SYK) Q1 2026 Press Conference Call Transcript
Stryker Corporation (SYK) Q1 2026 Press Conference Call Transcript
Stryker (SYK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Stryker to Report Q1 Earnings: What's in Store for the Stock?
SYK heads into Q1 earnings with strong procedure demand and robotic surgery growth, but tariff and cost pressures may test margins.
